FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1557220983> ?p ?o ?g. }

• W1557220983 endingPage "3" @default.
• W1557220983 startingPage "3" @default.
• W1557220983 abstract "Autism is complex neuro-developmental disorder which has a symptomatic diagnosis in patients characterized by disorders in language/communication, behavior, and social interactions. The exact causes for autism are largely unknown, but is has been speculated that immune and inflammatory responses, particularly those of Th2 type, may be involved. Thiazolidinediones (TZDs) are agonists of the peroxisome proliferator activated receptor gamma (PPARγ), a nuclear hormone receptor which modulates insulin sensitivity, and have been shown to induce apoptosis in activated T-lymphocytes and exert anti-inflammatory effects in glial cells. The TZD pioglitazone (Actos) is an FDA-approved PPARγ agonist used to treat type 2 diabetes, with a good safety profile, currently being tested in clinical trials of other neurological diseases including AD and MS. We therefore tested the safety and therapeutic potential of oral pioglitazone in a small cohort of children with diagnosed autism. The rationale and risks of taking pioglitazone were explained to the parents, consent was obtained, and treatment was initiated at either 30 or 60 mg per day p.o. A total of 25 children (average age 7.9 ± 0.7 year old) were enrolled. Safety was assessed by measurements of metabolic profiles and blood pressure; effects on behavioral symptoms were assessed by the Aberrant Behavior Checklist (ABC), which measures hyperactivity, inappropriate speech, irritability, lethargy, and stereotypy, done at baseline and after 3–4 months of treatment. In a small cohort of autistic children, daily treatment with 30 or 60 mg p.o. pioglitazone for 3–4 months induced apparent clinical improvement without adverse events. There were no adverse effects noted and behavioral measurements revealed a significant decrease in 4 out of 5 subcategories (irritability, lethargy, stereotypy, and hyperactivity). Improved behaviors were inversely correlated with patient age, indicating stronger effects on the younger patients. Pioglitazone should be considered for further testing of therapeutic potential in autistic patients." @default.
• W1557220983 created "2016-06-24" @default.
• W1557220983 creator A5011049361 @default.
• W1557220983 creator A5025549227 @default.
• W1557220983 creator A5036922002 @default.
• W1557220983 creator A5050207788 @default.
• W1557220983 creator A5079233160 @default.
• W1557220983 creator A5080669651 @default.
• W1557220983 creator A5088962222 @default.
• W1557220983 date "2007-01-01" @default.
• W1557220983 modified "2023-10-16" @default.
• W1557220983 cites W1581484826 @default.
• W1557220983 cites W1582022233 @default.
• W1557220983 cites W164830943 @default.
• W1557220983 cites W1656162023 @default.
• W1557220983 cites W1965733160 @default.
• W1557220983 cites W1966428366 @default.
• W1557220983 cites W1973548013 @default.
• W1557220983 cites W1977851224 @default.
• W1557220983 cites W1984127715 @default.
• W1557220983 cites W1990377340 @default.
• W1557220983 cites W1994275409 @default.
• W1557220983 cites W2000757610 @default.
• W1557220983 cites W2004265420 @default.
• W1557220983 cites W2004995928 @default.
• W1557220983 cites W2005149292 @default.
• W1557220983 cites W2006343974 @default.
• W1557220983 cites W2009755884 @default.
• W1557220983 cites W2017191185 @default.
• W1557220983 cites W2023422638 @default.
• W1557220983 cites W2025052824 @default.
• W1557220983 cites W2027699993 @default.
• W1557220983 cites W2030658245 @default.
• W1557220983 cites W2034421798 @default.
• W1557220983 cites W2039064135 @default.
• W1557220983 cites W2043038397 @default.
• W1557220983 cites W2044727648 @default.
• W1557220983 cites W2044771254 @default.
• W1557220983 cites W2045113312 @default.
• W1557220983 cites W2046352226 @default.
• W1557220983 cites W2054173272 @default.
• W1557220983 cites W2056804091 @default.
• W1557220983 cites W2057609336 @default.
• W1557220983 cites W2061440069 @default.
• W1557220983 cites W2063970310 @default.
• W1557220983 cites W2066962820 @default.
• W1557220983 cites W2069963174 @default.
• W1557220983 cites W2086756547 @default.
• W1557220983 cites W2088356767 @default.
• W1557220983 cites W2092691320 @default.
• W1557220983 cites W2095466964 @default.
• W1557220983 cites W2097813731 @default.
• W1557220983 cites W2098951793 @default.
• W1557220983 cites W2105854609 @default.
• W1557220983 cites W2112515017 @default.
• W1557220983 cites W2115243563 @default.
• W1557220983 cites W2115518955 @default.
• W1557220983 cites W2118725696 @default.
• W1557220983 cites W2123330148 @default.
• W1557220983 cites W2128011380 @default.
• W1557220983 cites W2129181263 @default.
• W1557220983 cites W2130382255 @default.
• W1557220983 cites W2136054045 @default.
• W1557220983 cites W2139475974 @default.
• W1557220983 cites W2158210077 @default.
• W1557220983 cites W2165881238 @default.
• W1557220983 cites W2169341678 @default.
• W1557220983 cites W2354770336 @default.
• W1557220983 cites W2408770126 @default.
• W1557220983 cites W2416469800 @default.
• W1557220983 cites W3192686273 @default.
• W1557220983 cites W4229611071 @default.
• W1557220983 doi "https://doi.org/10.1186/1742-2094-4-3" @default.
• W1557220983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1781426" @default.
• W1557220983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17207275" @default.
• W1557220983 hasPublicationYear "2007" @default.
• W1557220983 type Work @default.
• W1557220983 sameAs 1557220983 @default.
• W1557220983 citedByCount "98" @default.
• W1557220983 countsByYear W15572209832012 @default.
• W1557220983 countsByYear W15572209832013 @default.
• W1557220983 countsByYear W15572209832014 @default.
• W1557220983 countsByYear W15572209832015 @default.
• W1557220983 countsByYear W15572209832016 @default.
• W1557220983 countsByYear W15572209832017 @default.
• W1557220983 countsByYear W15572209832018 @default.
• W1557220983 countsByYear W15572209832019 @default.
• W1557220983 countsByYear W15572209832020 @default.
• W1557220983 countsByYear W15572209832021 @default.
• W1557220983 countsByYear W15572209832022 @default.
• W1557220983 countsByYear W15572209832023 @default.
• W1557220983 crossrefType "journal-article" @default.
• W1557220983 hasAuthorship W1557220983A5011049361 @default.
• W1557220983 hasAuthorship W1557220983A5025549227 @default.
• W1557220983 hasAuthorship W1557220983A5036922002 @default.
• W1557220983 hasAuthorship W1557220983A5050207788 @default.
• W1557220983 hasAuthorship W1557220983A5079233160 @default.
• W1557220983 hasAuthorship W1557220983A5080669651 @default.

• next